Good one-To The Moon - Tiger Brokers Online Investing Community - To The Moon

6
Comment
Favorite

jeffmum
2021-08-10

Good one

Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time

According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE

Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

6

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":896270320,"tweetId":"896270320","gmtCreate":1628588596660,"gmtModify":1703508641374,"author":{"id":3582787548532316,"idStr":"3582787548532316","authorId":3582787548532316,"authorIdStr":"3582787548532316","name":"jeffmum","avatar":"https://static.tigerbbs.com/3aaf38ada4e9468a5ba38839ff3b40a9","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good one</p></body></html>","htmlText":"<html><head></head><body><p>Good one</p></body></html>","text":"Good one","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/896270320","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","pubTimestamp":1628585720,"share":"https://www.laohu8.com/m/news/1122891084?lang=&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<ul>\n <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>\n <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>\n <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>\n <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>\n <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>\n <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>\n <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>\n <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>\n <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>\n <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>\n <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>\n <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>\n <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>\n <li>Israel has already started administering booster shots to people over the age of 60.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 16:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters ...</p>\n\n<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1},"isVote":1,"tweetType":1,"viewCount":510,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["AONE.U"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}